Sign in

    Daniel P. O’Day

    Chairman and Chief Executive Officer at Gilead Sciences Inc
    Board
    Since March 2019
    Age
    60 years
    Education
    Earned a bachelor's degree in biology from Georgetown University and an MBA from Columbia University.
    Tenure
    Joined GILD in March 2019 as both Chairman and Chief Executive Officer and has continued to lead the company since.

    Also at Gilead Sciences Inc

    ADD
    Andrew D. Dickinson
    Chief Financial Officer
    DHT
    Deborah H. Telman
    EVP, Corporate Affairs and General Counsel
    JM
    Johanna Mercier
    Chief Commercial Officer

    About

    Daniel P. O’Day is a seasoned executive with an extensive background in the pharmaceutical industry. Raised with a strong academic foundation, he built his early career on the principles of science and business management, having earned his degrees in biology and business administration from prestigious institutions.

    Before joining GILD, he amassed over three decades of experience at Roche Pharmaceuticals, where he held various executive roles and was instrumental in steering the company's pharmaceutical and diagnostics divisions across North America, Europe, and Asia. His leadership journey at Roche also included pivotal board roles with companies such as Genentech and Flatiron Health.

    Upon joining GILD in March 2019 as both Chairman and Chief Executive Officer, he brought his deep industry insights and commitment to innovation, driving the company’s strategy to address unmet medical needs and navigate evolving global healthcare challenges. His role has been central to enhancing the company’s pipeline and maintaining its leadership in the pharmaceutical market.

    In addition to his executive duties at GILD, he serves as the Board Chair for the Pharmaceutical Research and Manufacturers of America (PhRMA), underscoring his influential presence in shaping industry standards and advancing healthcare initiatives.

    $GILD Performance Under Daniel P. O’Day

    Past Roles

    OrganizationRoleDate RangeDetails
    Roche Pharmaceuticals Chief Executive Officer Before March 2019 Held various executive positions for over three decades across North America, Europe, and Asia
    Roche Pharmaceuticals Member, Corporate Executive Committee N/AServed as a member during his tenure with no specific dates provided
    Genentech Board Member N/ARole held as part of his involvement with several public and private boards
    Flatiron Health Board Member N/ARole held as part of his involvement with several public and private boards
    Foundation Medicine Board Member N/ARole held as part of his involvement with several public and private boards

    External Roles

    OrganizationRoleDate RangeDetails
    Pharmaceutical Research and Manufacturers of America (PhRMA) Board Chair N/ACurrent active role
    Galapagos NV Board Member N/AIn connection with its partnership with Gilead

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Salary$1,740,962 AnnuallyFixed annual salary
    Company Contributions to Deferred Compensation Plan$750,000 Annual installments (final installment of a 5-year agreement)Compensation for pension benefits forfeited with previous employer
    Insurance Premiums$7,482 AnnuallyLife insurance premiums
    Perquisites and Other Personal Benefits$1,192,990 AnnuallyIncludes corporate aircraft use ($233,596 ), personal security services ($166,859 ), corporate automobiles use ($28,283 ) and executive digital protection ($7,000 )

    Performance Compensation

    Data from  FY 2023

    Performance Shares

    Metric & DetailsValueCitations
    Performance Share TypeRelative TSR Tranche & Revenue Tranche (50% weight each)
    Performance Period (Relative TSR)March 1, 2023 - December 31, 2025
    2023 Revenue Goal (Revenue Tranche)$26.5 billion
    Threshold Shares3,155 shares
    Target Shares58,514 shares
    Maximum Shares117,028 shares
    Grant DateMarch 10, 2023
    Grant Date Fair Value$4,999,868
    Vesting ConditionMust remain employed through corresponding Relative TSR-based and Revenue-based Awards Certification Dates

    Corporate Bonus (Non-Equity Incentive Plan)

    Metric & DetailsValueCitations
    Target Corporate Bonus$2,625,000
    Maximum Bonus$5,250,000
    Base Salary$1,750,000
    Target Incentive Opportunity150% of base salary
    Total Award Value$4,036,200
    Performance Factor124% (tied to corporate performance)
    Performance Metrics100% corporate performance; specific quantitative metrics not provided
    Vesting/ConditionsNo detailed vesting schedule provided